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journal homepage: www.e-t jo.comEditorialChoose the right treatment for the right patientsAge-relatedmacular degeneration (AMD) is one of themajor causes
of adult visual loss. During the past decade, the use of anti-vascular
endothelial growth factor (anti-VEGF) agents for the treatment of
neovascular eye disease has signiﬁcantly changed the standard of
care in retinal medicine and ophthalmology. Intravitreal injection
of anti-VEGF drugs has since been widely employed clinically to
mitigate disease progression and improve the visual outcomes of
affected patients.
Although evidence-based data support the use of anti-VEGF
pharmacotherapy in neovascular AMD, not every patient responds
well to treatment. The factors contributing to the non-response
include genetic factors, presence of polypoidal choroidal vasculop-
athy, retinal angiomatous proliferation, presence of vitreoretinal
interface anomalies, or mimics of wet AMD.1e3 Some patients
respond to treatment, but progress to disciform scarring, retinal
pigment epithelial (RPE) tears, massive subretinal hemorrhage,
geographic atrophy, or develop tachyphylaxis to anti-VEGF drugs.4
While there is argument about the timing associated with the de-
cision of a responder to accept treatment, it would be helpful for
AMD patients if the efﬁcacy of anti-VEGF could be determined as
early as possible in their treatment, so that non-responders could
begin other more appropriate therapy. Evidence showed that
most diseases require long-term treatments to maintain the bene-
ﬁcial effects of the therapy, therefore, the treatment burden is sub-
stantial for both patients and doctors.5e7 Hence, it is important to
choose the appropriate therapy for an individual patient from the
beginning.
Macular telangiectasia type 2 (Mac Tel 2) is an importantmimics
of wet AMD. In this issue of the Taiwan Journal of Ophthalmology,
Wu8 contributes a comprehensive review of Mac Tel 2. Mac Tel 2,
also known as idiopathic perifoveal telangiectasia and juxtafoveo-
lar retinal telangiectasis type 2A, is an enigmatic disease of un-
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life. Clinical characteristics include minimally dilated parafoveal
capillaries with loss of retinal transparency in the area involved,
absence of lipid exudation, right-angled retinal venules, superﬁcial
retinal refractile deposits, hyperplasia of the RPE, foveal atrophy,
and choroidal neovacularization (CNV). Optical coherent tomogra-
phy (OCT) images typically demonstrate outer retinal abnormalities
and the presence of intraretinal hyporeﬂective spaces that are usu-
ally not related with retinal thickening or ﬂuorescein leakage. The
typical ﬂuorescein angiographic ﬁnding is a deep intraretinal
hyperﬂuorescent staining in the temporal parafoveal area. Over
time, this ﬂuorescein hyperﬂuorescence involves the entire parafo-
veal area, but does not extend to the center of the fovea. Long-term
prognosis for central vision is poor due to the development of CNV
or macular atrophy. Its pathogenesis remains unclear, however,
multimodality imaging with ﬂuorescein angiography, spectral
domain optical coherence tomography, adaptive optics, confocal
blue reﬂectance, short-wave fundus autoﬂuorescence, OCT angiog-
raphy, and clinicopathological correlations implicate Müller cells.
Currently there is no known treatment for this condition, unless
in the presence of CNV. The eyes of these patients may beneﬁt
from anti-VEGF treatment.9 It is important to choose the right treat-
ment at the right stage of Mac Tel 2. Otherwise, inaction may in-
crease the treatment-related risk and burden.
OCT is a non-invasive imaging modality that shows cross-
sectional images of the retina, RPE, and choroid. The recently devel-
oped OCT angiography provides the opportunity to study retinal
vasculature without the need for dye injection. OCT angiography
offered an even better tool to investigate the anatomical changes
associated with Mac Tel 2 and is expected to be a useful guide for
treatment. This treatment demonstrates that the earliest vascular
changes associated with Mac Tel 2 arise in the outer deep capillary
plexus.10,11 As the disease progresses, the vascular changes also
involve the inner superﬁcial plexus, albeit to a lesser extent than
the changes seen in the outer plexus.11 The vessels appear less
densely packed, thinner, and in an abnormal arrangement. The nor-
mally avascular Henle's layer and the outer nuclear layers becomes
the target of a vascular invasion. Anastomosis between plexi and
dragging of vessels temporally are also observed by OCT angiog-
raphy.10 Patients withMac Tel 2 could be monitored closely to catch
the right time for intervention.
Several ocular factors had been reportedly related to AMD prog-
ress.2,3 In this issue of the Taiwan Journal of Ophthalmology, Lai
et al12 report the relationship of distinct reduced subfoveal
choroidal thickness (SFCT) and elongated axial length (AL) with
late AMD. A total of 856 eyes of 486 patients (older than 65 years),
including 400 eyes at various AMD stages and 456 eyes with noier Taiwan LLC. All rights reserved.
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study. Their results showed that eyes with thinner SFCT and longer
AL showed high odds ratios (ORs) for late AMD, and even higher
ORswhen both factors were simultaneously present. These ﬁndings
illustrate the crucial pathophysiological role of these two important
ocular factors and arouse our attention to patients with both char-
acteristics, especially in Asian countries where the prevalence of
myopia is disturbingly high. The impacts of these study results on
treatment decision making deserve to be further clariﬁed.
In conclusion, the advances in the diagnosis andmanagement of
macular disease have made amazing progress in the past decade.
Although a variety of trials and studies showed the convincing ef-
fect of intravitreal pharmacotherapy by anti-VEGF, the optimal
treatment regime remained controversial. Improper treatment
caused waste of medical resources and increased treatment-
related risk for the patients. Current evidence supports the value
of individualized treatment for different individuals. We should al-
ways try to make the correct diagnosis and plan the treatment
based on individual factors.References
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